Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk
Menée au Canada auprès de 854 patientes atteintes d'un cancer épithélial de l'ovaire et auprès de 2 139 témoins (âge : 40 ans ou plus), cette étude évalue l'association entre l'utilisation, avant la première grossesse à terme, de contraceptifs oraux combinés et une réduction du risque de cancer épithélial de l'ovaire
Background : Combined oral contraceptive (COC) use reduces epithelial ovarian cancer (EOC) risk. However, little is known about risk with COC use before the first full-term pregnancy (FFTP).
Methods : This Canadian population-based case–control study (2001–2012) included 854 invasive cases/2139 controls aged greater than or equal to 40 years who were parous and had information on COC use. We estimated odds ratios (aORs) and 95% confidence intervals (CI) adjusted for study site, age, parity, breastfeeding, age at FFTP, familial breast/ovarian cancer, tubal ligation, and body mass.
Results : Among parous women, per year of COC use exclusively before the FFTP was associated with a 9% risk reduction (95% CI=0.86–0.96). Results were similar for high-grade serous and endometrioid/clear cell EOC. In contrast, per year of use exclusively after the FFTP was not associated with risk (aOR=0.98, 95% CI=0.95–1.02).
Conclusions : Combined oral contraceptive use before the FFTP may provide a risk reduction that remains for many years, informing possible prevention strategies.
British Journal of Cancer , résumé, 2015